Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGOG-cx3: Doxorubicin vs doxorubicin + atezolizumab in recurrent cervical cancer
2016-000547-14Phase 2Completed
- Sponsor
- Belgian Gynaecological Oncology Group - UZ Leuven
- Start
- Jul 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of atezolizumab in cervical cancer (mCC) (2 arms), sponsored by Belgian Gynaecological Oncology Group - UZ Leuven. Primary endpoints: Safety and tolerability of atezolizumab and Overall survival. Started Jul 2017; status: completed.
02
Drugs
atezolizumab
03
Conditions
cervical cancer (mCC)
Beyond the preview
Go deeper on 2016-000547-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000547-14.